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S U M M A R Y
Background: High rates of antimicrobial resistance in Escherichia coli isolated from patients with urinary
tract infections have been reported worldwide. The aim of this study was to identify risk factors for
resistance to ciproﬂoxacin (CIP) and cefotaxime (CTX) in E. coli isolated from patients with acute
pyelonephritis (APN).
Methods: We prospectively identiﬁed women over 18 y of age who visited the emergency department of
one of 10 hospitals with APN and whose urine culture grew E. coli. The study was conducted from April 16
to June 10, 2012.
Results: Of the 229 patients identiﬁed, 173 (75.5%) had community-associated (CA) infections and 56
(24.5%) had healthcare-associated (HCA) infections. Sixty-seven isolates (29.3%) were resistant to CIP, 45
(19.7%) to CTX, and 29 (12.7%) to both CIP and CTX. Multivariate analyses revealed that hematologic
disease, chronic kidney disease, a bed-ridden state, indwelling urinary catheter, antibiotic treatment in
the preceding 3 months, and isolation of CIP-resistant E. coli in the urine within the preceding 3 months,
were signiﬁcantly associated with resistance to both CIP and CTX.
Conclusions: Chronic conditions and healthcare-associated factors were related to resistance to both
ﬂuoroquinolones and third-generation cephalosporins in women with APN. Continued and vigilant
surveillance is necessary to monitor the dissemination of antimicrobial resistance in uropathogens.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Urinary tract infections (UTIs) are the second cause of
community-onset infection.1 Almost half of all women have a
UTI during their lifetime.2 Escherichia coli is the single most
common uropathogen, causing 75–95% of all uncomplicated
cystitis and pyelonephritis cases in women.3 Due to theciety for Infectious Diseases. Open access under CC BY-NC-ND license.
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as trimethoprim–sulfamethoxazole (TMP–SMX), guidelines for the
treatment of community-onset UTI recommend ﬂuoroquinolones
as ﬁrst-line empiric therapy in communities in which TMP–SMX
resistance in uropathogens is >10–20% and the ﬂuoroquinolone
resistance rate is <10%.1,4,5
Lately, antimicrobial resistance in uropathogenic E. coli has
been increasing globally.6,7 A recent surveillance study of
inpatients with community-onset UTI in the USA, documented a
high rate of resistance to ciproﬂoxacin (CIP) in E. coli, up to 32.4%.8
In E. coli isolated from patients with community-onset UTI, the rate
of CIP resistance in Greece was 36.4% from 2000 to 2002,9 whereas
it was less than 5% in other European countries.10 In Korea, the rate
of CIP resistance in E. coli has been shown to range from 15.9% to
23.5% in patients with community-onset acute pyelonephritis
(APN).11,12 In addition, the increasing prevalence of extended-
spectrum b-lactamase (ESBL) in uropathogenic E. coli, frequently
with cross-resistance to ﬂuoroquinolones, has become a major
concern.13 In some European countries, the prevalence of ESBL-
producing E. coli in patients with community-onset UTI increased
to 1.7–6.3% over the last decade.14,15 The rate of E. coli non-
susceptible to cefotaxime (CTX) in inpatients with community-
onset UTI was found to be 8.6% in the USA.8 The rate of ESBL-
producing (or resistant to third-generation cephalosporin) E. coli in
patients with community-onset UTI was reported at 4.6–8.9% in
Korea.11,12,16–18
Patients with a UTI caused by resistant pathogens are at risk of
receiving inappropriate empiric antibiotic therapy, resulting in
increased morbidity.12,19–21 Although discordant empiric therapy
with ﬂuoroquinolones does not affect overall mortality or the
clinical cure rate,12,19,20 it results in a lower microbiological cure
rate19 and longer hospital stay12,20 than concordant therapy in
community-onset APN. In patients with APN caused by ESBL-
producing E. coli, inappropriate empiric therapy has been shown to
result in persistent fever, progression of the infection, and a longer
hospital stay.21
Therefore, it is of clinical relevance to identify factors associated
with antimicrobial resistance in order to improve the chance of
choosing an appropriate empiric antibiotic in patients with
community-onset UTI. Accordingly, the aim of this study was to
determine demographic and clinical factors associated with CIP-
and/or CTX-resistant E. coli in female patients presenting to the
emergency department with APN.
2. Methods
2.1. Patients and setting
This study was conducted at 10 hospitals in Korea from April 16
to June 10, 2012. We prospectively screened the urine culture
results of the microbiology laboratory database and identiﬁed
women over 18 y of age whose urine culture was performed in the
emergency department and grew E. coli. Polymicrobial cases were
excluded. After reviewing the medical records, patients with APN
were enrolled in the study. The following data were collected by
means of a standardized form: demographic characteristics,
signiﬁcant comorbidities, information on urinary tract abnormali-
ties and the presence of a urinary catheter, other medical
conditions, hospitalization during the preceding 6 months,
antibiotic exposure during the preceding 90 days, culture results
of previous urine specimens within 3 months, and antimicrobial
susceptibilities of the E. coli isolates. For patients presenting more
than once during the study period, only the ﬁrst episode was
included. This study was approved by the institutional review
board at each hospital.2.2. Deﬁnitions
APN was deﬁned in the presence of fever (body temperature
38 8C) and/or a history of fever and chills within 24 h before
presentation, at least one symptom of UTI (dysuria, frequency,
urgency, perineal pain, ﬂank pain, or costovertebral tenderness),
and a positive nitrite dipstick test, or leukocyturia as deﬁned by a
positive leukocyte esterase dipstick test, or the presence of 5
leukocytes per high-power ﬁeld in a centrifuged specimen.22 A
recurrent UTI was deﬁned as three or more UTIs in the preceding
12 months, or two or more UTIs in the preceding 6 months.23 A
complicated UTI was deﬁned by one or more of the following: (1)
the presence of an indwelling catheter or the use of intermittent
catheterization; (2) >100 ml of residual urine retained after
voiding; (3) obstructive uropathy due to bladder outlet obstruc-
tion, a calculous, or other cause; (4) vesicoureteral reﬂux or other
urologic abnormalities, including surgically created ileal loops; (5)
azotemia due to intrinsic renal disease, even in the absence of
deﬁned structural abnormalities of the urinary tract; and (6) renal
transplantation.24 Chronic kidney disease was deﬁned as creati-
nine clearance <60 ml/min/1.73 m2.25
APN was further classiﬁed as either healthcare-associated or
community-associated. Healthcare-associated APN (HCA-APN)
was deﬁned according to the modiﬁed criteria of Friedman
et al.,26 as follows: (1) the patient received intravenous therapy,
wound care, or specialized nursing care at home during the 30 days
before APN; (2) the patient attended a hemodialysis clinic or
received intravenous chemotherapy in the 30 days before the
infection; (3) the patient had been hospitalized for acute care for 2
or more days in an acute care hospital in the 90 days preceding the
infection; (4) the patient resided in a nursing home or long-term
care facility; or (5) the patient received an invasive urinary
procedure, urological surgery, or urethral catheterization within
the 30 days before APN. If the patient did not fulﬁll any of the above
criteria, the episode was deﬁned as community-associated (CA-
APN).
2.3. Antibiotic susceptibility testing
Antibiotic susceptibility testing was performed using the semi-
automated system VITEK II (bioMe´rieux, Hazelwood, MO, USA) or
MicroScan (Dade Behring, West Sacramento, CA, USA) at each
hospital. The antimicrobial susceptibility of E. coli isolates was
determined based on the standards of the Clinical and Laboratory
Standards Institute.27 Isolates showing intermediate antimicrobial
susceptibility were considered to be resistant.
2.4. Statistical analysis
Continuous data were compared with the Student’s t-test, or
the Mann-Whitney U-test when the distribution departed from
normality. Categorical data were analyzed by Chi-square or
Fisher’s exact test, as appropriate. Any variable with a p-value
<0.1 in the univariate analysis was included in the binary logistic
regression as a dependent variable. Statistical signiﬁcance was
deﬁned as a two-tailed p-value of <0.05. Statistical analyses were
carried out with IBM SPSS Statistics for Windows, version 20.0
(IBM Corp., Armonk, NY, USA).
3. Results
During the 8-week study period, 229 patients with APN caused
by E. coli were identiﬁed. The median age of patients was 69
(interquartile range 55–76) years. One hundred seventy-three
cases (75.5%) were CA-APN and 56 (24.5%) were HCA-APN
(Table 1). Sixty-seven E. coli isolates (29.3%) were resistant to
Table 1
Antimicrobial resistance between community-associated and healthcare-associated APN caused by Escherichia colia
E. coli isolate resistant to: Total
(n = 229)
Community-associated
(n = 173)
Healthcare-associated
(n = 56)
p-Valueb
Ciproﬂoxacin 67 (29.3) 39 (22.5) 28 (50.0) <0.001
Cefotaxime 45 (19.7) 23 (13.3) 22 (39.3) <0.001
Gentamicin 60 (26.2) 35 (20.3) 25 (44.6) <0.001
Trimethoprim–sulfamethoxazole 72 (31.4) 48 (27.7) 24 (42.9) 0.03
Ciproﬂoxacin and cefotaxime 29 (12.7) 12 (6.9) 17 (30.4) <0.001
APN, acute pyelonephritis.
a Data are presented as the number of patients (%).
b Between community-associated and healthcare-associated cases.
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isolates in patients with HCA-APN were more resistant to all
antibiotics tested than those of CA-APN. Signiﬁcant numbers of E.
coli isolates of CA-APN were also resistant to CIP (22.5%), CTX
(13.3%), and both antibiotics (6.9%).
3.1. Factors associated with ciproﬂoxacin- or cefotaxime-resistant E.
coli
Patients with CIP-resistant E. coli were more likely to have
diabetes mellitus or a neurologic disease and to have had antibiotic
treatment in the preceding 3 months. They were in a bed-ridden
state more frequently than those with CIP-susceptible E. coli
(Table 2). Healthcare-associated and complicated UTIs were also
more frequent in patients with CIP resistance than in those without
CIP resistance.
Patients with CTX-resistant E. coli were more likely to have
healthcare-associated and complicated APN and an underlying
disease such as hematologic disease, diabetes mellitus, or
pancreaticobiliary disease. They were more frequently in a bed-
ridden state. These patients had also received antibiotic treatment
in the preceding 3 months and isolation of CIP-resistant E. coli in
the urine within the preceding 3 months more frequently than
those without CTX resistance.Table 2
Analysis of APN caused by Escherichia coli according to ciproﬂoxacin or cefotaxime res
Variable CIP-
resis
(n = 
Age, years, median (IQR) 71 (
Underlying disease 58 (
Cardiovascular disease 38 (
Diabetes mellitus 31 (
Neurologic disease 20 (
Solid tumor 6 (
Hematologic disease 3 (
Chronic liver disease 2 (
Pancreaticobiliary disease 2 (
Chronic pulmonary disease 2 (
Connective tissue disease 1 (
Others 11 (
Bed-ridden state 12 (
Antibiotic treatment in the preceding 3 months 19 (
Healthcare-associated APN 28 (
Recurrent UTI 7 (
Complicated UTI 26 (
Chronic kidney disease 9 (
Obstructive uropathy 8 (
Indwelling urinary catheter 7 (
Residual urine (>100 ml) 3 (
Intermittent catheterization 2 (
Vesicoureteral reﬂux or other urological abnormalities 1 (
Isolation of CIP-resistant E. coli in the urine within the preceding 3 months 8 (
Isolation of CTX-resistant E. coli in the urine within the preceding 3 months 9 (
APN, acute pyelonephritis; CIP, ciproﬂoxacin; CTX, cefotaxime; IQR, interquartile range
a Data are presented as the number of patients (%) unless indicated otherwise.Multivariate analyses revealed that CIP resistance was signiﬁ-
cantly associated with neurologic disease, antibiotic treatment in
the preceding 3 months, and complicated UTI (Table 3). CTX
resistance was associated with HCA-APN, hematologic disease, and
chronic kidney disease.
3.2. Factors associated with ciproﬂoxacin- and cefotaxime-resistant E.
coli
Factors including healthcare-associated or complicated UTI,
underlying diseases such as pancreaticobiliary disease, hemato-
logic disease, and neurologic disease, a bed-ridden state, and
antibiotic treatment in the preceding 3 months were signiﬁcantly
associated with CIP and CTX resistance (Table 4). Multivariate
analyses revealed that, compared to patients without resistance to
CIP and CTX, hematologic disease, chronic kidney disease, a bed-
ridden state, indwelling urinary catheter, antibiotic treatment in
the preceding 3 months, and isolation of CIP-resistant E. coli in the
urine within the preceding 3 months, were signiﬁcantly associated
with resistance to both CIP and CTX (Table 3).
4. Discussion
In this study, antimicrobial resistance in uropathogenic E. coli
was found to be alarmingly high, and isolates were resistant toistance (n = 229)
tant
67)
CIP-
susceptible
(n = 162)
p-Value CTX-
resistant
(n = 45)
CTX-
susceptible
(n = 184)
p-Value
59–77) 67 (50–76) 0.56 71 (62–76) 68 (51–76) 0.04
86.6) 113 (69.8) 0.008 40 (88.9) 131 (71.2) 0.01
56.7) 74 (45.7) 0.13 27 (60.0) 85 (46.2) 0.1
46.3) 54 (33.3) 0.07 24 (53.3) 61 (33.2) 0.01
29.9) 20 (12.3) 0.002 11 (26.7) 28 (15.2) 0.07
9.0) 10 (6.2) 0.45 6 (13.3) 10 (5.4) 0.06
4.5) 2 (1.2) 0.15 4 (8.9) 1 (0.5) 0.006
3) 4 (2.5) 1.0 2 (4.4) 4 (2.2) 0.34
3) 0 0.09 2 (4.4) 0 0.04
3) 4 (2.5) 1.0 1 (2.2) 5 (2.7) 1.00
1.5) 3 (1.9) 1.0 1 (2.2) 3 (1.6) 0.59
16.4) 27 (16.7) 0.96 8 (17.8) 30 (16.3) 0.81
17.9) 6 (3.7) <0.001 7 (15.6) 11 (6.0) 0.03
28.4) 18 (11.1) 0.001 15 (33.3) 22 (12.0) <0.001
41.8) 28 (17.3) <0.001 22 (48.9) 34 (18.5) <0.001
10.4) 10 (6.2) 0.26 6 (13.3) 11 (6.0) 0.09
38.8) 20 (12.3) <0.001 18 (40.0) 28 (15.2) <0.001
13.4) 8 (4.9) 0.03 10 (22.2) 7 (3.8) <0.001
11.9) 9 (5.6) 0.09 4 (8.9) 13 (7.1) 0.75
10.4) 2 (1.2) 0.003 4 (8.9) 5 (2.7) 0.08
4.5) 3 (1.9) 0.36 1 (2.2) 5 (2.7) 1.0
3) 0 0.09 1 (2.2) 1 (0.5) 0.36
1.5) 1 (0.6) 0.5 0 2 (1.1) 1.00
11.9) 3 (1.9) 0.003 6 (13.3) 5 (2.7) 0.003
13.4) 8 (4.9) 0.03 4 (8.9) 13 (7.1) 0.75
; UTI, urinary tract infection.
Table 3
Multivariate analyses of factors associated with resistance to ciproﬂoxacin,
cefotaxime, or both antibiotics
Variable OR (95% CI) p-Value
Resistance to CIP
Neurologic disease 2.9 (1.29–6.42) 0.01
Antibiotic treatment in
the preceding 3 months
2.3 (1.05–5.24) 0.04
Complicated UTI 3.5 (1.64–7.30) 0.001
Resistance to CTX
Hematologic disease 16.8 (1.61–174.94) 0.02
Chronic kidney disease 6.1 (2.00–18.78) 0.001
Healthcare-associated APN 3.8 (1.76–8.07) 0.001
Resistance to both CIP and CTX
Hematologic disease 17.3 (1.32–226.6) 0.04
Chronic kidney disease 6.8 (1.52–30.07) 0.01
Indwelling urinary catheter 9.4 (1.14–78.09) 0.04
Bed-ridden state 7.5 (1.70–33.46) 0.02
Antibiotic treatment in the
preceding 3 months
3.8 (1.18–12.54) 0.004
Isolation of CIP-resistant E. coli in
the urine within the
preceding 3 months
5.8 (1.07–37.79) 0.04
APN, acute pyelonephritis; CI, conﬁdence interval; CIP, ciproﬂoxacin; CTX,
cefotaxime; OR, odds ratio.
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Studies have reported the rates of CIP resistance to be higher in
complicated UTI than in uncomplicated UTI,11,28 or in healthcare-
associated UTI than in community-associated UTI.16,29,30 A
previous study showed that empiric antibiotic therapy was
inadequate in healthcare-associated UTI patients more frequently
than in those with community-associated UTI, although not
statistically signiﬁcantly.31 These ﬁndings suggest that patients
with healthcare-associated UTI should be differentiated from those
with community-associated UTI to avoid treatment failure and
reduce morbidity.
The rate of CIP resistance in the present cohort was 29.3%,
which is consistent with the ﬁndings of other studies on
community-onset APN in Korea.11,12 Several clinical factorsTable 4
Analysis of APN caused by ciproﬂoxacin- and cefotaxime-resistant Escherichia colia
Variable 
Age, years, median (IQR) 
Underlying disease 
Cardiovascular disease 
Diabetes mellitus 
Neurologic disease 
Hematologic disease 
Solid tumor 
Chronic liver disease 
Pancreaticobiliary disease 
Chronic pulmonary disease 
Connective tissue disease 
Others 
Bed-ridden state 
Antibiotic treatment in the preceding 3 months 
Healthcare-associated APN 
Recurrent UTI 
Complicated UTI 
Chronic kidney disease 
Indwelling urinary catheter 
Intermittent catheterization 
Residual urine (>100 ml) 
Obstructive uropathy 
Vesicoureteral reﬂux or other urological abnormalities 
Isolation of CIP-resistant E. coli in the urine within the preceding 3 months 
Isolation of CTX-resistant E. coli in the urine within the preceding 3 months 
APN, acute pyelonephritis; CIP, ciproﬂoxacin; CTX, cefotaxime; IQR, interquartile range
a Data are presented as the number of patients (%) unless indicated otherwise.including neurologic disease, antibiotic treatment in the preceding
3 months, and complicated UTI were associated with CIP resistance
in this study. These ﬁndings are in accordance with those of
previous UTI studies of community-onset APN, which have found
prior exposure to ﬂuoroquinolones,9,22,32–36 previous hospitaliza-
tion,22,33,34 recurrent UTI,34,36 the presence of complicated UTI,35
previous invasive procedure,34 urinary catheter in the preceding 6
months,22 chronic disease,9 and age over 50 years,35 to be
associated with resistance to CIP or levoﬂoxacin in uropathogenic
E. coli. In the present study, factors including HCA-APN, hemato-
logic disease, and chronic kidney disease were signiﬁcantly
associated with CTX resistance, which is also consistent with
the ﬁndings of other studies. Previous studies have shown that, in
patients with community-onset UTI, the isolation of ESBL-
producing Enterobacteriaceae is independently associated with
prior use of antibiotics,14–16,18,37,38 healthcare-associated infec-
tion,16 previous hospitalization in the preceding 3 months,38
previous invasive procedures of the urinary tract,37 urinary
catheterization during the preceding month,18 recurrent
UTI,15,37 underlying condition,18 diabetes mellitus,37,38 prostatic
disease,15 follow-up in outpatient clinic,37 old age,37,38 and
gender.37,38
Resistance to both CIP and CTX, when compared with patients
without resistance to CIP and CTX, was associated with hemato-
logic disease, chronic kidney disease, a bed-ridden state, indwell-
ing urinary catheter, antibiotic treatment in the preceding 3
months, and isolation of CIP-resistant E. coli in the urine within the
preceding 3 months. Overall, factors that were found to be related
to CIP and/or CTX resistance mechanisms in this study were
healthcare-associated and overlapped in terms of antibiotic
resistance. However, the numbers of patients who had each risk
factor were small to moderate. These ﬁndings indicate a poor
predictive value of risk factors for antimicrobial resistance, as
described in a previous study.39 The unavailability of speciﬁc and
reliable risk factors for antimicrobial resistance may result in the
selection of antibiotics to which the organism is non-susceptibleCIP- and CTX-
resistant
(n = 29)
CIP- and CTX-susceptible
(n = 146)
p-Value
72 (64–77) 67 (48–76) 0.06
25 (86.2) 98 (67.1) 0.04
18 (62.1) 65 (44.5) 0.08
16 (55.2) 46 (31.5) 0.02
9 (31.0) 17 (11.6) 0.007
3 (10.3) 1 (0.7) 0.02
3 (10.3) 7 (4.8) 0.37
2 (6.9) 4 (2.7) 0.26
2 (6.9) 0 0.03
1 (3.4) 4 (2.7) 1.00
1 (3.4) 3 (2.1) 0.52
5 (17.2) 24 (16.4) 0.92
7 (24.1) 6 (4.1) <0.001
12 (41.4) 15 (10.3) <0.001
17 (58.6) 23 (15.8) <0.001
3 (10.3) 7 (4.8) 0.37
13 (44.8) 15 (10.3) <0.001
7 (24.1) 5 (3.4) <0.001
4 (13.8) 2 (1.4) 0.007
1 (3.4) 0 0.17
1 (3.4) 3 (2.1) 0.52
1 (3.4) 6 (4.1) 1.00
0 1 (0.7) 1.00
6 (20.7) 3 (2.1) 0.001
4 (13.8) 8 (5.5) 0.12
; UTI, urinary tract infection.
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community-associated UTIs.
It is of note that signiﬁcant numbers of patients with CA-APN
caused by CIP- and/or CTX-resistant E. coli had no healthcare-
associated factors (Table 1). A recent study in the USA revealed that
a substantial proportion of community-onset UTI caused by ESBL-
producing E. coli occurred among patients without discernible
healthcare-associated risk factors.40 In that study, of the 291
patients with community-onset ESBL-producing E. coli infections,
36.8% were community-associated (81.5% of which represented
UTI), while the remainder were healthcare-associated.40
These ﬁndings are of great concern, since third-generation
cephalosporins and ﬂuoroquinolones are both ﬁrst-line agents
for the empiric treatment of community-onset UTI, especially in
regions where the prevalence of E. coli resistant to TMP–SMX
exceeds 20%.1 This epidemiological shift has implications for the
empiric management of community-onset UTI. For serious
community-onset APN with risk factors for antibiotic resistance,
carbapenems or aminoglycosides should be considered for initial
empiric therapy,5 although inappropriate empiric therapy does
not lead to increased mortality.12,19–21
The present study had limitations. First, in this prospective but
observational study, antibiotic use in the study patients may have
been underestimated since there may have been antibiotics that
were prescribed in other hospitals. Second, the clinical outcome
was not analyzed; therefore, the impact of antimicrobial resistance
could not be assessed. Third, the results of this study may
exaggerate the antimicrobial resistance of uropathogenic E. coli
and not reﬂect that of the primary care setting, as the investigation
was conducted in university-afﬁliated hospitals. Fourth, since the
results pertained only to female patients presenting to the
emergency department with APN, these ﬁndings may not be
extrapolated to male patients or those with mild UTIs who visit the
outpatient clinic. In addition, there might be a selection bias
toward more severe cases or patients with severe underlying
diseases, because only patients who visited the emergency
department were evaluated. Nevertheless, choosing effective
empiric antibiotics is more relevant for these vulnerable patients
than any other patient group. Finally, the exact mechanisms of
antimicrobial resistance were not identiﬁed for antimicrobial
resistance phenotypes (for example, ESBL production versus CTX
resistance).
In summary, resistance to ﬂuoroquinolones and third-genera-
tion cephalosporins in E. coli was very high in women presenting to
the emergency department with APN. Chronic conditions and
healthcare-associated factors were related to resistance to both
classes of antibiotics; however, a signiﬁcant number of cases of
community-associated APN without those factors were also noted.
Continued and vigilant surveillance is necessary to monitor the
dissemination of antimicrobial resistance in uropathogens.
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